| |
| |
|
| Insider
Information: |
Baker Felix |
| Relationship: |
Director, 10% Owner |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
20 |
|
| Direct
Shares |
927,207 |
|
|
Indirect Shares
|
141,861,898 |
|
|
| Direct
Value |
$78,351,502 |
|
|
|
Indirect Value
|
$12,714,980,768 |
|
|
| Total
Shares |
142,789,105 |
|
|
| Total
Value |
$12,793,332,270 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
36
|
6
|
|
Stock
price went up :
|
15
|
6
|
| Stock
price went down : |
21
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
6.0
|
| Percentage
Gain/Loss : |
 -24.3%
|
 18.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Incyte Corp |
INCY |
Director, 10% Owner |
2023-09-29 |
559,963 |
2023-09-29 |
33,480,292 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2003-10-06 |
0 |
2012-02-01 |
116,454 |
Premium* |
|
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2018-02-01 |
215,015 |
2018-02-01 |
44,355,335 |
Premium* |
|
|
Synageva BioPharma Corp |
GEVA |
Director, 10% Owner |
2015-06-22 |
100,503 |
2015-06-22 |
9,328,233 |
Premium* |
|
|
Viropharma Inc |
VPHM |
10% Owner |
2005-01-31 |
0 |
2011-12-14 |
303,264 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2017-07-03 |
145,453 |
Premium* |
|
|
Tapestry Pharmaceuticals Inc |
TPPHQ |
10% Owner |
|
0 |
2008-10-15 |
0 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2012-10-01 |
288 |
2012-10-01 |
11,377,485 |
Premium* |
|
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
|
0 |
2009-02-06 |
1,629 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
10% Owner |
2016-08-16 |
46,918 |
2016-08-16 |
9,418,390 |
Premium* |
|
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2011-06-30 |
5,266,568 |
Premium* |
|
|
Adolor Corp |
ADLR |
10% Owner |
2010-04-26 |
0 |
2011-12-19 |
0 |
Premium* |
|
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2010-07-28 |
140,525 |
Premium* |
|
|
Pharmacyclics Inc |
PCYC |
10% Owner |
|
0 |
2011-08-22 |
1,809 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
57,704 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2012-10-29 |
0 |
2012-10-29 |
480,639 |
Premium* |
|
|
Neurogene |
NGNE |
10% Owner |
2015-08-07 |
4,520 |
|
0 |
Premium* |
|
|
Invitae Corp |
NVTA |
10% Owner |
|
0 |
2015-08-27 |
6,554,967 |
Premium* |
|
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
|
0 |
2015-12-24 |
4,865,647 |
Premium* |
|
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2022-01-21 |
0 |
2022-06-06 |
15,967,504 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| INCY |
Incyte Corp |
Director |
– • • |
2023-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,020 |
33,446,882 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,024 |
33,446,372 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2023-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
5,010 |
33,445,860 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-12-30 |
4 |
A |
$0.00 |
$0 |
I/I |
794 |
33,422,926 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-09-30 |
4 |
A |
$0.00 |
$0 |
I/I |
914 |
33,422,529 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
866 |
33,422,072 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-06-15 |
4 |
A |
$0.00 |
$0 |
I/I |
4,288 |
33,421,639 |
0 |
- |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-06-06 |
4 |
B |
$7.75 |
$2,361,093 |
I/I |
303,917 |
15,967,504 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-06-03 |
4 |
B |
$7.93 |
$812,481 |
I/I |
102,200 |
15,695,640 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-06-02 |
4 |
B |
$7.51 |
$1,274,594 |
I/I |
166,232 |
15,604,214 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-27 |
4 |
B |
$6.64 |
$1,071,030 |
I/I |
155,940 |
15,455,507 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-26 |
4 |
B |
$6.71 |
$628,583 |
I/I |
93,322 |
15,316,021 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-25 |
4 |
B |
$6.53 |
$664,135 |
I/I |
101,144 |
15,232,546 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-18 |
4 |
B |
$5.95 |
$1,335,419 |
I/I |
223,766 |
15,142,074 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-17 |
4 |
B |
$5.99 |
$663,571 |
I/I |
110,824 |
14,942,601 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-05-16 |
4 |
B |
$5.71 |
$697,839 |
I/I |
122,100 |
14,843,809 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
I/I |
880 |
33,419,495 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-03-10 |
4 |
B |
$71.90 |
$15,982,720 |
I/I |
218,563 |
33,419,055 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-03-09 |
4 |
B |
$71.72 |
$5,057,550 |
I/I |
70,517 |
33,217,136 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-03-08 |
4 |
OE |
$22.05 |
$882,000 |
I/I |
40,000 |
33,059,604 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-03-08 |
4 |
B |
$70.68 |
$7,067,500 |
I/I |
100,000 |
33,151,989 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-02-22 |
4 |
B |
$68.07 |
$6,793,536 |
I/I |
99,800 |
33,039,604 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-02-18 |
4 |
B |
$68.37 |
$9,096,550 |
I/I |
133,032 |
32,947,370 |
2.25 |
% |
|
| INCY |
Incyte Corp |
Director |
– • • |
2022-02-17 |
4 |
B |
$67.40 |
$19,844,805 |
I/I |
292,972 |
32,824,461 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2022-02-17 |
4 |
B |
$53.82 |
$16,367,881 |
I/I |
300,000 |
14,734,965 |
2.25 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
